Fermentalg (FALG) H1 2025 TU earnings summary

Executive summary

• Achieved half-year sales of €7.6M for H1 2025, up 20% year-over-year and 57% above the five-year average.

• Maintains strong commercial momentum in Europe, with over 80% of sales from the region.

• Expanding into new segments: pet food, infant nutrition, and aquaculture, while dietary supplements remain over 60% of sales.

Financial highlights

• H1 2025 sales reached €7.6M, setting a new record for the company.

• Sales growth of 20% compared to H1 2024.

Outlook and guidance

• Reaffirms target of at least €25M in annual sales by 2026, over six times 2023 levels.

• 2025 expected to align with analyst consensus and strategic growth trajectory.